Clinical and immunohistochemical study of eight cases with thymic carcinoma

被引：28

作者：

Tomita M. ^{[1
]}

Matsuzaki Y. ^{[1
]}

Edagawa M. ^{[1
]}

Maeda M. ^{[1
]}

Shimizu T. ^{[1
]}

Hara M. ^{[1
]}

Onitsuka T. ^{[1
]}

机构：

[1] Department of Surgery II, Miyazaki Medical College, Kiyotake, Miyazaki, 889-1692

来源：

BMC Surgery | / 2卷 / 1期

关键词：

Vascular Endothelial Growth Factor; Squamous Cell Carcinoma; Thymoma; Microvessel Density; Small Cell Carcinoma;

D O I：

10.1186/1471-2482-2-3

中图分类号：

学科分类号：

摘要：

Background: Thymic carcinoma is a rare neoplasm with extremely poor prognosis. To evaluate the biological characteristics of thymic carcinoma, we reviewed 8 patients. Methods: There were 2 men and 6 women: ages ranged from 19 to 67 years old (mean 54.8 years). None of these patients had concomitant myasthenia gravis and pure red cell aplasia. No patient had stage I disease, 1 stage II, 5 stage III, and 2 stage IV. The pathologic subtypes of thymic carcinoma included 5 squamous cell carcinomas, 1 adenosquamous cell carcinomas, 1 clear cell carcinoma, and 1 small cell carcinoma. Immunohistochemical study was performed using antibodies against p53, bcl-2, Ki-67, carcinoembryonic antigen (CEA), epithelial membrane antigen (EMA), nm23-H1, vascular endothelial growth factor (VEGF), basic fibroblast growth factor (FGF-2) and factor VIII. Results: Curative resection could be done in 4 patients (50%). Our data indicates a trend toward an association between complete resection and patient survival. Expression of p53, bcl-2, CEA, EMA, nm23-H1, VEGF and FGF-2 was detected in 5/8, 3/8, 4/8, 5/8, 6/8, 5/8 and 3/8, respectively. (Mean Ki-67 labeling index and microvessel density was 7.01 and 34.36 (per 200x field), respectively. When compared with our previous studies, immunohistochemical staining of these proteins in thymomas, the expression rates of these proteins in thymic carcinomas were higher than those in thymomas. Conclusions: In this small series, it is suggested that a complete resection suggests a favorable result. Immunohistochemical results reveal that the expression of these proteins might indicate the aggressiveness of thymic carcinoma.

引用

页码：1 / 6

页数：5

共 22 条

[1] Levine G.D., Rosai J., Thymic hyperplasia and neoplasia: A review of current concepts, Hum Pathol, 9, pp. 495-514, (1978)
[2] Wick M.R., Weiland L.H., Scheithauer B.W., Bernatz P.E., Primary thymic carcinomas, Am J Surg Pathol, 6, pp. 451-470, (1982)
[3] Truong L.D., Mody D.R., Cagle P.T., Jackson Y.G., Schwartz M.R., Wheeler T.M., Thymic carcinoma. A clinicopathologic study of 13 cases, Am J Surg Pathol, 14, pp. 151-166, (1990)
[4] Suster S., Rosai J., Thymic carcinoma. A clinicopathologic study of 60 cases, Cancer, 67, pp. 1025-1032, (1991)
[5] Hsu C.P., Chen C.Y., Chen C.L., Lin C.T., Hsu N.Y., Wang J.H., Wang P.Y., Thymic carcinoma. Ten years' experience in twenty patients, J Thorac Cardiovasc Surg, 107, pp. 615-620, (1994)
[6] Blumberg D., Burt M.E., Bains M.S., Downey R.J., Martini N., Rusch V., Ginsberg R.J., Thymic carcinoma: Current staging does not predict prognosis, J Thorac Cardiovasc Surg, 115, pp. 303-308, (1998)
[7] Chung D.A., Thymic carcinoma-analysis of nineteen clinicopathological studies, Thorac Cardiovasc Surg, 48, pp. 114-119, (2000)
[8] Liu H.C., Hsu W.H., Chen Y.J., Chan Y.J., Wu Y.C., Huang B.S., Huang M.H., Primary thymic carcinoma, Ann Thorac Surg, 73, pp. 1076-1081, (2002)
[9] Tateyama H., Eimoto T., Tada T., Mizuno T., Inagaki H., Hata A., Sasaki M., Masaoka A., p53 protein expression and p53 gene mutation in thymic epithelial tumors. An immunohistochemical and DNA sequencing study, Am J Clin P, 104, pp. 375-381, (1995)
[10] Hayashi Y., Ishii N., Obayashi C., Jinnai K., Hanioka K., Imai Y., Itoh H., Thymoma: Tumour type related to expression of epidermal growth factor (EGF), EGF-receptor, p53, v-erb B and ras p21, Virchows Arch, 426, pp. 43-50, (1995)

← 1 2 3 →